Federal Register Notice: FDA is making available a draft guidance for industry entitled Pulmonary Tuberculosis: Developing Drugs for Treatment. It aims to assist sponsors in developing antimycobacterial drugs for treating pulmonary tuberculosis. It applies to a single investigational drug as well as two or more unmarketed investigational drugs for use in combination. To download this guidance, click here. To view this notice, click here.
